Until recently, the traditional treatment for primary or metastatic liver tumors has been surgical resection. However, only 25% of those with liver metastases are candidates for surgery because of the size, distribution, or accessibility of their tumors. Also, the morbidity rate for surgery is high. Therapeutic alternatives are needed because the incidence of new liver metastases following successful resection of metastases is high—with 60% to 80%. Many studies have shown that large liver resections stimulate many growth factors, including growths of micrometastases, which are potentially somewhere else in the liver. This is probably the reason why many patients develop new metastases already in the first year after surgical resection. Furthermore, there are indicators that the stimulation of the growth factors after surgical resection is not only stimulating the development of new metastases within the liver, but also outside the liver, such as in the lung or lymph nodes. Chemotherapy is still widely used to treat liver metastases. However, the survival is still limited and many patients suffer from relevant side effects. Therefore, minimal invasive tumor ablation using the LITT technique helps to improve survival and should be routinely considered in an adapted oncologic concept including surgery, chemotherapy, and ablation.